Cardiocentro Ticino News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cardiocentro ticino. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cardiocentro Ticino Today - Breaking & Trending Today

Even Less Aspirin With Ticagrelor-Based DAPT Safe After Stenting for ACS

T-PASS trial weighs stopping aspirin within a month ....

South Korea , New York , United States , Soult Ukpyolsi , South Korean , Roisin Colleran , B Hadley Wilson , Marco Valgimigli , Cardiocentro Ticino , Ajay Kirtane , Ticagrelor Brilinta , American College Of Cardiology , Presbyterian Columbia University Irving Medical Center , Yonsei University College Of Medicine , Cardiovascular Research Institute Dublin , Academic Research Consortium , Cardiovascular Research Foundation , Severance Hospital , Yonsei University College , Transcatheter Cardiovascular Therapeutics , Cardiovascular Research , Columbia University Irving Medical Center , John Messenger , Colorado Cardiac Catheterization Labs , American College , Bleeding Academic Research Consortium ,

Bleeding as Mortality Surrogate Questioned for Antithrombotic Trials

New research argues combining study outcomes in a NACE endpoint may muddy the waters a win ratio may be better. ....

New York , United States , Toshiki Kuno , Marco Valgimigli , Cardiocentro Ticino , American College Of Cardiology World Congress , Phd Montefiore Medical Center , Albert Einstein College Of Medicine , Montefiore Medical Center , Albert Einstein College , American College , World Congress ,

MELOS: LBB Area Pacing Promising for Bradyarrhythmias, HF

The large European study suggests the technique may be viable but also has a stiff learning curve and can result in a "wide spectrum" of complications. ....

United States , Angelo Auricchio , Marek Jastrz , Cardiocentro Ticino , European Heart Rhythm Association , Jagiellonian University , Multicentre European , Venus De Milo , Heart Rhythm Association , Presented April , Heart Failure , Implanted Device Cardiology , Biventricular Pacing , Cardiac Resynchronization Therapy , Clinical Research , Clinical Trials , Linical Studies , Medical Literature ,

TAVI Beneficial Even in Eldest Patients, Registry Reaffirms

April 19, 2021
Observational data from Switzerland add support to the idea that age shouldn’t be a barrier to TAVI, researchers say. While nonagenarian patients in the SwissTAVI Registry had a higher mortality risk compared with younger TAVI patients, these individuals were no more likely to die than people of similar age in the general population.
The question of how well the very elderly fare after TAVI is of increasing importance as the global population ages. By 2050, there will be around 76.7 million people older than 90 years, many of whom will develop aortic stenosis and face the choice of whether to undergo an invasive procedure. ....

Nordrhein Westfalen , Adrian Attinger Toller , Ricardoo Esc , Enrico Ferrari , Cardiocentro Ticino , Brian Hummel , Eberhard Grube , Phd University Hospital Bonn , Lee Health System , University Heart Center , Md University , Hospital Fribourg , University Hospital Bonn , Fort Myers , னோற்ர்ேன் வெஸ்ட்ஃபாலன் , பிரையன் ஹம்மல் , எபர்ஹாஎச் க்ருபே , ஃப்ட் பல்கலைக்கழகம் மருத்துவமனை பொன் , லீ ஆரோக்கியம் அமைப்பு , பல்கலைக்கழகம் இதயம் மையம் , ம்ட் பல்கலைக்கழகம் , பல்கலைக்கழகம் மருத்துவமனை பொன் , கோட்டை மைஸ் ,

Abbott's XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients

Press release content from PR Newswire. The AP news staff was not involved in its creation.
Abbott’s XIENCE™ Stent Receives European Approval for One-Month Dual Anti-Platelet Therapy (DAPT) for High Bleeding Risk Patients
April 6, 2021 GMT
ABBOTT PARK, Ill., April 6, 2021 /PRNewswire/ Abbott (NYSE: ABT) today announced its XIENCE stent has received CE Mark in Europe for shorter duration of dual anti-platelet therapy (DAPT) – as short as 28 days, the shortest indication available in the world – for patients with high bleeding risk (HBR). The approval follows recent results from two studies that demonstrated both one-month or three-month DAPT followed by aspirin monotherapy is safe in HBR patients and is intended to improve patient outcomes and provide physicians more options to treat their patients. XIENCE is the most widely used stent worldwide and is the only stent to have evidence and data for both one-month and three-months DAPT followed by two different t ....

Marco Valgimigli , Cardiocentro Ticino , University Of The Italian Switzerland , Italian Switzerland , Nick West , பல்கலைக்கழகம் ஆஃப் தி இத்தாலிய சுவிட்சர்லாந்து , இத்தாலிய சுவிட்சர்லாந்து , நிக் மேற்கு ,